Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 2, 2012-02 ,pp. : 151-162

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

By Eiermann W.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

By Zagouri Flora  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 13-22

Springer Publishing Company

Access to resources Recommend Favorite